Moin!

On behalf of the Scientific Committee, we are pleased to invite you to the 1st Joint Educational Meeting of the Chronic Malignancies Working Party (CMWP) and the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT, to be held in Hamburg, Germany, on 24th to 26th November 2023. This event will present the most recent advances and new perspectives in the field of immunology and cellular therapy for multiple myeloma and plasma disorders, including current practical challenges and new patient-centered perspectives.

The plenary conference programme is designed to place emphasis on leading-edge basic and clinical research. This shall be a platform for deliberate interaction, sharing of experiences and active and open scientific discourse and debate. Everything will be embedded in the Beauty of Germany's north, Hamburg, with a dedicated and warm environment for active networking.

Annalisa Ruggeri, CTIWP Chair  
Donal McLornan, CMWP Chair  
Nico Gagelmann, local organiser
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:00 - 13:00| **Chronic Malignancies Working Party Scientific Business Meeting**  
Open for everybody |
| 13:00 - 14:00| Lunch Break                                               |
| 14:00 - 16:00| **Chronic Malignancies Working Party Scientific Business Meeting**  
Open for everybody |
| 16:00 - 16:15| Coffee Break                                              |
| 16:15 - 17:15| Joint Meeting                                              |
| 17:15 - 18:00| **Keynote Lecture**                                       |
|              | Placement of cellular therapies in treatment algorithm of PCDs  
Carlos Fernández de Larrea (ES) |

**Breakout Room**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 10:30 - 13:00| **Cellular Therapy and Immunobiology Working Party Scientific Business Meeting**  
Open for everybody |
| 13:00 - 14:00| Lunch Break                                               |
| 14:00 - 16:00| **Cellular Therapy and Immunobiology Working Party Scientific Business Meeting**  
Open for everybody |
| 16:00 - 16:15| Coffee Break                                              |
| 16:15 - 17:15| Joint Meeting at Plenary Room                            |
Saturday, 25 November 2023

**Plenary Room**

**Session I: Basics of myeloma**

*Chair: Meral Bekscac (TR)*

- 09:00-09:15 Diagnostic and treatment algorithm in MM  
  Patrick Hayden (IE)
- 09:15-09:30 Diagnostic and treatment algorithm in amyloidosis  
  Monique Minnema (NL)
- 09:30-09:45 Diagnostic and treatment algorithm in WM, MGCS, MGRS  
  Shirley D'Sa (UK)
- 09:45-10:00 Q&A

**Session II: Preclinical models in MM**

*Chair: Florent Malard (FR)*

- 10:00-10:15 Genomic evolution  
  Niels Weinhold (DE)
- 10:15-10:30 Omics  
  Marc Raab (DE)
- 10:30-10:45 Microbiome  
  Florent Malard (FR)
- 10:45-11:00 Q&A

**Coffee Break**

**Session III: Immune microenvironment in disease**

*Chairs: Joanna Drozd-Sokolowska (PL) - Kavita Raj (UK)*

- 11:30-11:45 T-cells  
  Kim de Veirman (NL)
- 11:45-12:00 NK cells  
  Michael O’Dwyer (IE)
- 12:00-12:15 Mechanisms of EMD  
  Tomáš Jelinek (CZ)
- 12:15-12:30 Case presentation: Refractory Multiple Myeloma with Challenging Extramedullary Disease  
  Esra Gülderen (TR)
- 12:30-12:45 Q&A

**Session IV: Novel cellular therapies**

*Chair: Lydia Lee (UK)*

- 12:35-12:45 Novel targets  
  Luis G. Rodríguez-Lobato (ES)
- 12:45-12:55 NK cells, macrophages, fibroblasts  
  Niels Weinhold (DE)
- 12:55-13:05 Harvesting the therapeutic potential of gdT cells for cancer immune therapies  
  Jürgen Kuball (NL)
- 13:05-13:15 Immune signalling at the tumour: bone marrow niche in multiple myeloma: a view to a kill  
  Graeme Sullivan (IE)
- 13:15-13:30 Q&A

**Lunch Break**
14:30 – 15:15  
**Session V: Procedural aspects**  
*Chair: Stefan Schönland (DE)*  
14:30-14:45  
Cell collection and manufacturing  
Christian Chabannon (FR)  
14:45-15:00  
AI  
Alexander Oeser (DE)  
15:00-15:15  
Q&A

15:15 – 16:00  
**Session VI: New and "old" kids on the block**  
*Chair: Gösta Gahrton (SE)*  
15:15-15:30  
Finding the optimal drug combination for rrMM  
Fredrik Schjesvold (NO)  
15:30-15:45  
Role of autograft  
Mauricette Michallet (FR)  
15:45-16:00  
Q&A

16:00 – 16:30  
Coffee Break

16:30 – 17:30  
**Session VII: Current state of CAR-T in PCD**  
*Chair: Nico Gagelmann (DE)*  
16:30-16:45  
Ide-cel and cilt-cel: trial insights  
Yael Cohen (IL)  
16:45-17:00  
Real-world and GOCART  
Nico Gagelmann (DE)  
17:00-17:15  
Academic  
Lydia Lee (UK)  
17:15-17:30  
Q&A

17:30 – 18:15  
**Keynote lecture**  
*Chair: Anna Sureda (ES)*  
Lessons and new insights in allogeneic CAR-T and transplant  
Nicolaus Kröger (DE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:10 – 09:15</td>
<td>Welcome</td>
<td></td>
</tr>
<tr>
<td>09:15 – 10:15</td>
<td>Session I: Multiple myeloma, the basics, and new treatment options</td>
<td>Laurent Garderet (FR)</td>
</tr>
<tr>
<td>09:15–10:15</td>
<td>Multiple myeloma (the basics), new treatment options, and what's important in the patients screening for CART cell therapy in the MM field (frail/unfit screening)</td>
<td></td>
</tr>
<tr>
<td>10:15 – 11:00</td>
<td>Session II (part I): Toxicity during CART cell therapy and bispecific</td>
<td>Maaike de Ruijter (NL)</td>
</tr>
<tr>
<td>10:15–11:00</td>
<td>CAR-T</td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:15</td>
<td>Session II (part II): Toxicity during CART cell therapy and bispecific</td>
<td>Marianne Elshoud (NL)</td>
</tr>
<tr>
<td>11:30–12:15</td>
<td>Bispecifics</td>
<td></td>
</tr>
<tr>
<td>12:15 – 13:15</td>
<td>Session III: The role of the research nurse and nurse specialist in the patient Pathway (CART and bispecific)</td>
<td>Sandy Kruyswijk (NL), Maaike de Ruijter (NL)</td>
</tr>
<tr>
<td>12:15–12:45</td>
<td>CAR-T</td>
<td></td>
</tr>
<tr>
<td>12:45–13:15</td>
<td>Bispecifics</td>
<td></td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Closing Remarks</td>
<td></td>
</tr>
<tr>
<td>13:30–14:30</td>
<td>Lunch Break</td>
<td></td>
</tr>
</tbody>
</table>
Sunday, 26 November 2023

**Plenary Room**

### 09:00 - 10:00
**Session VIII: Biology of response and relapse**
*Chair: Annalisa Ruggeri (IT)*
- **09:00-09:15** High-risk Myeloma transplant vs CART  
  Christoph Schaefers (DE)
- **09:15-09:30** Antigen loss and microenvironment  
  Sarah Gooding (UK)
- **09:30-09:45** Immune monitoring  
  Christof Scheid (DE)
- **09:45-10:00** Q&A

### 10:00 - 10:55
**Industry Symposium on “Novel therapies in multiple myeloma”**
*Kindly sponsored by Janssen*
*Chair: Hermann Einsele (DE)*
- **10:00-10:10** Novel immune and cellular therapies  
  Hermann Einsele (DE)
- **10:10-10:25** CAR T cells - patient selection and treatment of toxicities  
  Christof Scheid (DE)
- **10:25-10:40** Management of infections & mitigations strategies  
  Cyrus Khandanpour (DE)
- **10:40-10:55** Q&A

### 10:55 – 11:25
**Coffee Break**

### 11:25 – 12:25
**Session IX: Monitoring and treating resistance**
*Chair: Yael Cohen (IL)*
- **11:25-11:40** Multi-targeting  
  Mohamad Mohty (FR)
- **11:40-11:55** Role of MRD  
  Noemi Puig (ES)
- **11:55-12:10** Bispecifics  
  Hermann Einsele (DE)
- **12:10-12:25** Q&A

### 12:25 – 13:25
**Session X: Patient fitness and toxicities**
*Chair: Donal McLornan (UK)*
- **12:25-12:40** Is there “eligibility” for CAR-T?  
  Laurent Garderet (FR)
- **12:40-12:55** Mechanisms and strategies for neurotoxicity  
  Ibrahim Yakoub-Agha (FR)
- **12:55-13:10** Hematotoxicity and others  
  Meral Beksac (TR)
- **13:10-13:25** Q&A

### 13:25 – 13:40
**Closing Remarks**
Donal McLornan (UK)
Annalisa Ruggeri (IT)